By targeting an individual CRL, we gain specificity and have the potential to see improved efficacy‐to‐toxicity ratios in tumours that are dependent upon a particular E3 without the broad toxicity of agents like proteasome inhibitors or pevonedistat that target broader swaths of the UPS. The gene discussed is IL31RA; the disease is neoplasm.